HC Wainwright Issues Optimistic Forecast for TCRX Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Analysts at HC Wainwright increased their Q2 2025 EPS estimates for shares of TScan Therapeutics in a report released on Wednesday, May 7th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.29) per share for the quarter, up from their prior estimate of ($0.32). HC Wainwright currently has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics' Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.18) EPS, FY2026 earnings at ($1.15) EPS, FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.31) EPS.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. The firm had revenue of $2.17 million for the quarter, compared to analysts' expectations of $1.62 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

A number of other research firms have also issued reports on TCRX. Wedbush reaffirmed an "outperform" rating and set a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, May 6th. Barclays dropped their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Needham & Company LLC restated a "buy" rating and set a $9.00 target price on shares of TScan Therapeutics in a report on Tuesday, April 8th. Finally, Morgan Stanley restated an "overweight" rating and issued a $10.00 price target on shares of TScan Therapeutics in a research report on Friday, March 14th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $8.50.

TScan Therapeutics Price Performance

Shares of TCRX traded down $0.01 during midday trading on Monday, reaching $1.31. The stock had a trading volume of 34,975 shares, compared to its average volume of 361,264. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The company has a market capitalization of $73.85 million, a P/E ratio of -1.23 and a beta of 1.06. The firm's 50 day moving average price is $1.44 and its 200-day moving average price is $2.62. TScan Therapeutics has a 52 week low of $1.02 and a 52 week high of $9.69.

Hedge Funds Weigh In On TScan Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its position in shares of TScan Therapeutics by 31.2% in the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company's stock worth $62,000 after buying an additional 4,852 shares during the period. Wells Fargo & Company MN boosted its position in TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after acquiring an additional 5,694 shares during the period. Wellington Management Group LLP grew its stake in TScan Therapeutics by 5.2% during the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company's stock valued at $404,000 after acquiring an additional 6,550 shares in the last quarter. Woodline Partners LP increased its holdings in shares of TScan Therapeutics by 6.7% in the 4th quarter. Woodline Partners LP now owns 115,866 shares of the company's stock valued at $352,000 after purchasing an additional 7,282 shares during the period. Finally, Aberdeen Group plc lifted its position in shares of TScan Therapeutics by 0.9% in the first quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock worth $1,230,000 after purchasing an additional 7,744 shares in the last quarter. Institutional investors and hedge funds own 82.83% of the company's stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.